Kevin Ka-Ho Kam

Kevin Ka-Ho Kam

Auto-generated profile, based on publicly available information

Kevin Ka-Ho Kam

Division of Cardiology, Department of Medicine and Therapeutics, Prince of Wales Hospital, Chinese University of Hong Kong, Hong Kong SAR, China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YFYiting Fan
Yiting Fan
TCTsz-Ngai Chan
Tsz-Ngai Chan
JCJosie T. Y. Chow
Josie T. Y. Chow
KKKevin K. H. Kam
Kevin K. H. Kam
WCWai-Kin Chi
Wai-Kin Chi
ALAlex Lee
Alex Lee
Left ventricular hypertrophy (LVH) caused by cardiac variant Fabry disease (FD) is typically late-onset and may mimic LVH caused by abnormal loading conditions. We aimed to determine the prevalence of FD in a non-selective patient population of everyday practice presenting with LVH, including those with hypertension and valve disease. We measured plasma alpha-galactosidase A activity using dried blood spot tests in 499 (age = 66 ± 13 years; 336 men) Hong Kong Chinese patients with LVH defined as maximal LV septal/posterior wall thickness ≥13 mm on echocardiography. Patients with low enzyme activity underwent mutation analysis of the GLA gene. Eight (age = 53−74 years; all men) unrelated patients (1.6%) had low plasma alpha-galactosidase A activity (0.57 ± 0.27 μmol/L wb/hr) and all were confirmed to have the GLA IVS4 + 919G > A mutation. FD patients presented with heart failure (n = 5), heart block (n = 2), ventricular tachycardia (n = 1), chest pain (n = 3), and/or murmur (n = 1). Uncontrolled hypertension (n = 4) and/or severe mitral/aortic valve pathology (n = 2) were frequent. Ethnic subgroups included Teochew (n = 5), Canton (n = 2), and Wenzhou (n = 1). Endomyocardial biopsy (n = 6) revealed hypertrophic myocytes with vacuolization and dense lamellar bodies. Late-onset IVS4 + 919G > A FD is prevalent among Chinese LVH patients, and should be considered as a cause of LVH in adult patients even when hypertension and/or valve pathology are present.

17 December 2024 in JACC: Asia
Verified
Journal Article
Open access
KSKent Chak-Yu So
Kent Chak-Yu So
JXJianqiang Xu
Jianqiang Xu
KKKevin Ka-Ho Kam
Kevin Ka-Ho Kam
SSShih-Hsien Sung
Shih-Hsien Sung
KMKrissada Meemook
Krissada Meemook
YLYat-Yin Lam
Yat-Yin Lam
Transcatheter tricuspid interventions are becoming increasingly more common in Asia Pacific. In the past decade, clinicians in Asia Pacific have worked with a multitude of new transcatheter tricuspid technologies. A standardized clinical algorithm to diagnose symptomatic tricuspid regurgitation to increase patient access to novel right heart therapies has not yet been identified. Anatomic diversity in the Asia Pacific patient population; disease prevalence patterns; and socioeconomic, cultural, and local health structures represent unique challenges in the treatment of these patients with right heart failure. As advancements are made in right heart failure and transcatheter tricuspid technologies, hopefully more patients can be treated not just in Asia Pacific, but across the entire world.

1 May 2021 in EuroIntervention
Verified
Journal Article
Open access
CSChak-Yu So
Chak-Yu So
SLShuang Li
Shuang Li
Guohua FuGuohua Fu
Guohua Fu
WCWei Chen
Wei Chen
KKKevin Ka-Ho Kam
Kevin Ka-Ho Kam
YLYat-Yin Lam
Yat-Yin Lam
The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

30 September 2022 in Nutrients
Verified
Journal Article
Open access
PDF file
JNJack KC Ng
Jack KC Ng
GCGordon Chun Kau Chan
Gordon Chun Kau Chan
KKKevin Ka-Ho Kam
Kevin Ka-Ho Kam
Na TianNa Tian
Na Tian
WTWin Hlaing Than
Win Hlaing Than
Philip Kam-tao LiPhilip Kam-tao Li
Philip Kam-tao Li
Patients treated with peritoneal dialysis (PD) experience complex body composition changes that are not adequately reflected by traditional anthropometric parameters. While lean and adipose tissue mass can be readily assessed by bioimpedance spectroscopy (BIS), there is concern about the potential confounding effect of volume overload on these measurements. This study aimed to assess the influence of fluid status (by echocardiography) on body composition parameters measured by BIS and to describe the longitudinal changes in adipose and lean tissue mass. We conducted a prospective observational study in a tertiary hospital. Incident Chinese PD patients underwent baseline echocardiography and repeated BIS measurements at baseline and 12 months later. Among 101 PD patients, lean tissue index (LTI) or fat tissue index (FTI) was not associated with echocardiographic parameters that reflected left ventricular filling pressure (surrogate of volume status). Sixty-eight patients with repeated BIS had a significant increase in body weight and FTI, while LTI remained similar. Gains in fat mass were significantly associated with muscle wasting (beta = −0.71, p < 0.0001). Moreover, progressive fluid accumulation independently predicted decrease in FTI (beta = −0.35, p < 0.0001) but not LTI. Body composition assessments by BIS were not affected by fluid status and should be considered as part of comprehensive nutrition assessment in PD patients.

24 September 2025 in JACC: Asia
Verified
Journal Article
Open access
KSKent Chak-Yu So
Kent Chak-Yu So
KMKrissada Meemook
Krissada Meemook
JXJianqiang Xu
Jianqiang Xu
CCChun-Chin Chang
Chun-Chin Chang
TNTawai Ngernsritrakul
Tawai Ngernsritrakul
YLYat-Yin Lam
Yat-Yin Lam
Tricuspid regurgitation (TR) causes significant morbidity. Transcatheter edge-to-edge repair (TEER) has been proven effective in relieving TR symptoms. Access to tricuspid TEER and the associated experience are limited in Asia. This study aimed to summarize the initial experience with the tricuspid TEER system (Abbott) in Asia. Patients undergoing tricuspid TEER (Abbott) from 2017 to 2024 were enrolled from 4 centers in Asia. The primary endpoint was device success (TR ≤moderate) at 30 days. Secondary endpoints included inpatient complications, 30-day NYHA functional class, and 30-day major adverse events. Risk factors for 30-day device success were identified. A total of 106 patients were included, with a mean age of 76.1 ± 10 years, and 88.7% (n = 94 of 106) had atrial fibrillation. Most TR cases treated were functional (88.7% [n = 94 of 106]), with over half classified as massive or torrential (56.6% [n = 60 of 106]). Tricuspid TEER was performed using off-label MitraClip in 22.6% (n = 24), while the remaining 77.4% (n = 82) utilized TriClip. Combined procedures (with mitral TEER and others) were common (47.2% [n = 50 of 106]). At 30 days, 74.0% (n = 77 of 104) achieved device success (TR ≤moderate), and 95.2% (n = 99 of 104) experienced at least a 1-grade TR reduction. Additionally, 96.2% (n = 100 of 104) were NYHA functional class I/II, and major adverse events were 1.9% (n = 2 of 106) at 30 days. Baseline nontorrential TR and increased clinical experience (second half of cases) were associated with 30-day device success (P = 0.010 and P = 0.044, respectively). The early experience with tricuspid TEER in Asia is promising, demonstrating a reasonable device success rate and a high safety profile. Clinical experience is associated with improved device success.

Verified
Journal Article
Open access
PDF file
SLSophia Po-Yee Leung
Sophia Po-Yee Leung
SDScott Dougherty
Scott Dougherty
XZXiaoyu Zhang
Xiaoyu Zhang
KKKevin K. H. Kam
Kevin K. H. Kam
WCWai-Kin Chi
Wai-Kin Chi
ALAlex Lee
Alex Lee
Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder that commonly manifests cardiovascular complications. We aimed to assess the prevalence of FD in a Chinese population with left ventricular hypertrophy (LVH) whilst implementing a gender-specific screening approach. Methods: Patients with LVH, defined as a maximum thickness of the left ventricular septal/posterior wall ≥ 13 mm, were considered eligible. All patients with hypertrophic cardiomyopathy (HCM) were excluded. Plasma α-galactosidase (α-GLA) enzyme activity was assessed using a dried blood spot test. Males with low enzyme activity underwent genetic testing to confirm a diagnosis of FD whereas females were screened for both α-GLA and globotriaosylsphingosine concentration and underwent genetic analysis of the GLA gene only if testing positive for ≥1 parameter. Results: 426 unrelated patients (age = 64.6 ± 13.0 years; female: male = 113:313) were evaluated. FD was diagnosed in 3 unrelated patients (age = 69.0 ± 3.5 years, female: male = 1:2) and 1 related female subject (age = 43 years). Genetic analyses confirmed the late-onset cardiac variant GLA c.640-801G>A (n = 3) and the missense variant c.869T>C associated with classic FD (n = 1). Cardiac complications were the only significant findings associated with the late-onset c.640-801G>A mutation, manifesting as mild or severe concentric LVH. In contrast, the classic c.869T>C mutation FD exhibited multisystemic manifestations in addition to severe concentric LVH. Conclusions: The prevalence of FD is lower in Chinese patients with LVH when HCM is excluded. The pathological variant c.640-801G>A remains the most common cause of late-onset FD, while the detection of FD in females can be improved by utilizing a gender-specific screening method.